T-Neuro Pharma is set to present new research at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, on October 31, showcasing an expanded version of its T-Track blood biomarker assay for Alzheimer's disease (AD). The company's presentation will highlight progress in broadening the applicability of this innovative diagnostic tool, potentially impacting early detection and monitoring of the disease.
The presentation, titled "Levels of age-related CD8 T cells binding HLA track with Alzheimer's disease status in HLA-A2+ and HLA-A2- patients: expansion of a flow cytometric blood biomarker assay to all patients," will be delivered by Christopher Wheeler, Ph.D., CSO of T-Neuro Pharma.
Key Findings on Expanded T-Track Assay
The original T-Track assay, which identifies changes in blood T cells corresponding to AD by counting T cells recognizing a specific peptide+HLA-A2, was previously limited to patients expressing HLA-A2. The new research addresses this limitation by assessing whether T-Track could be expanded to HLA-A2-negative patients by counting T cells that recognized HLA irrespective of peptide and A2 subtype.
Results demonstrated that even with lower levels of T cells bound to HLA in HLA-A2-negative patients, their binding corresponds with AD status with similar accuracy as the original assay. This finding provides a foundation for expanding T-Track to all patients, including minorities with proportionally more HLA-A2-negative individuals.
Implications for Alzheimer's Detection
"We are excited to share these promising results with the scientific community at CTAD," said Wheeler. "Our findings suggest that we can potentially make the T-Track assay accessible to a much broader patient population, which could significantly impact early detection and monitoring of Alzheimer's."
The expansion of the T-Track assay to include HLA-A2-negative patients represents a significant step forward in Alzheimer's diagnostics. By making the assay accessible to a broader patient population, T-Neuro Pharma aims to improve early detection and monitoring of Alzheimer's, potentially leading to earlier intervention and improved patient outcomes.
